BioSpace News Archive

It concerns the following four notifications:

Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.85 per share.

Mr. Nuerge had a long and distinguished career in the pharmaceutical industry, including serving as CEO of Shire US and Xanodyne Pharmaceuticals until his retirement.

The results of these studies again demonstrate the benefits of breast cancer subtyping using MammaTyper to predict the course of the disease and to aid in the selection of effective, tailored therapy.

Galera Therapeutics today announced data from its Phase 2b clinical trial of lead product candidate GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer will be presented.

The company has developed a novel technology to overcome limitations in the current approach to bifurcation lesions in coronary angioplasties.

This complex operation was successfully performed by Dr. Theodore Belanger at the Texas Health Presbyterian Hospital and positions Spineway as an innovative player in the treatment of scoliosis.

Ipsen announced that irinotecan liposome injection (Onivyde), cabozantinib (Cabometyx), lanreotide (Somatuline Autogel / Depot), and telotristat ethyl (Xermelo) are the subject of 11 posters, along with 2 others focusing on patients living with neuroendocrine tumors, at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO-GI), January 18-20, 2018 in San Francisco (CA, USA).

The biotech giant employs about 20,000 people worldwide.

The collaboration will allow e-Therapeutics to apply Intellegens’ technology to the predication and error correction of large-scale biological and chemical data.